Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

·¹Æ®·Î¹ÙÀÌ·¯½º º¤Å͸¦ ÀÌ¿ëÇÑ ÀÎü ¾Ï¼¼Æ÷ÁÖ·ÎÀÇ À¯ÀüÀÚ Àü´Þ È¿À² Comparison of Efficiency of Infection of Human Cancer Cell Lines Via Retroviral Vector System

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 1È£ p.1 ~ 10
±è¿¬¼ö, ÀÌ¿ëÁÖ, ¹ÎÁø½Ä, ÀÓÈñ°æ,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿¬¼ö (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¾Ï¿¬±¸¼Ò

ÀÌ¿ëÁÖ (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¾Ï¼¾ÅÍ
¹ÎÁø½Ä (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¾Ï¼¾ÅÍ
ÀÓÈñ°æ (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¾Ï¿¬±¸¼Ò

Abstract

°á·Ð
¹ÚÅ׸®¾ÆÀÇ lacZ À¯ÀüÀÚ¿Í neor marker À¯ÀüÀÚ¸¦ codingÇÏ°í ÀÖ´Â ·¹Æ®·Î¹Ù
ÀÌ·¯½º º¤ÅÍ LN ¥âZ DNA¸¦ mouse ¼¼Æ÷¿¡¸¸ È¿À²ÀûÀ¸·Î °¨¿°ÇÏ´Â ecotropic ÀçÁ¶ÇÕ ·¹Æ®
·Î¹ÙÀÌ·¯½º¸¦ ¾ò±â À§ÇØ ecotropic packaging cell line ¥×-2 ¼¼Æ÷µéÀ» calcium phosphate
coprecipitation ¹æ¹ý¿¡ ÀÇÇØ transfection½ÃÄÑ transfectionµÈ ¼¼Æ÷·ÎºÎÅÍ ¸¸µé¾îÁ® ¼¼Æ÷ ¹ÛÀ¸
·Î À¯ÃâµÈ ÀçÁ¶ÇÕ ·¹Æ®·Î¹ÙÀÌ·¯½º¸¦ Æ÷ÇÔÇÏ°í ÀÖ´Â ¹èÁö¸¦ ¾ò¾ú´Ù. ÀÌ·¸°Ô ¾òÀº ecotropic
ÀçÁ¶ÇÕ ·¹Æ®·Î¹ÙÀÌ·¯½º ÀÔÀÚ(LN ¥âZ)¸¦ °¡Áö°í amphotropic packaging cell line PA317 ¼¼
Æ÷µéÀ» °¨¿°½ÃŲ µÚ, G418-resistant colonyµéÀÌ »ý±æ ¶§±îÁö ¼±º° ¹è¾çÇÏ°í, °¢ colonyµéÀ»
ºÐ¸®ÇÏ¿© ÀÌ Áß ³ôÀº titerÀÇ ¹ÙÀÌ·¯½º¸¦ »ý»êÇÏ´Â ¼¼Æ÷ÁÖ¸¦ ¼±º°Çϱâ À§ÇØ, NIH/3T3 ¼¼Æ÷
¸¦ target cell·Î ÇÏ¿© titrationÀ» ½ÃÇàÇÏ¿© ÀÌ Áß °¡Àå ³ôÀº titer(1¡¿107
cfu/ml)ÀÇ ÀçÁ¶ÇÕ ·¹Æ®·Î¹ÙÀÌ·¯½º LN ¥âZ¸¦ »ý»êÇÏ´Â ¼¼Æ÷ÁÖ(PA317/LN ¥âZ)¸¦ ¼±º°ÇÏ¿´
´Ù. ÀÌ·¸°Ô ¼±º°µÈ ³ôÀº titerÀÇ ÀçÁ¶ÇÕ retrovirus¸¦ »ý»êÇÏ´Â producer cell line PA317/LN
¥âZ·ÎºÎÅÍ º¹Á¦°¡ °¡´ÉÇÏ°í °¨¿°¼ºÀÌ ÀÖ´Â replication competent retrovirus(RCR)°¡ ¸¸µé¾î
Á® ¹æÃâµÇ´Â ÁöÀÇ ¿©ºÎ´Â ÀÓ»ó Àü ½ÇÇè¿¡¼­ ·¹Æ®·Î¹ÙÀÌ·¯½º º¤ÅͽýºÅÛÀÇ È¿À²À» Á¶»çÇÏ´Â
µ¥¿¡µµ ¸Å¿ì Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇÑ´Ù. ±×·¯¹Ç·Î marker rescue ¹æ¹ýÀ» »ç¿ëÇÏ¿©
PA317/LN ¥âZ ¼¼Æ÷·ÎºÎÅÍ RCRÀÌ ¸¸µé¾îÁö´ÂÁö Á¶»çÇÑ °á°ú RCRÀÌ ¸¸µé¾îÁöÁö ¾Ê´Â´Ù´Â
°ÍÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù. ÇöÀç »ç¿ëµÇ°í ÀÖ´Â ·¹Æ®·Î¹ÙÀÌ·¯½º º¤ÅÍ ½Ã½ºÅÛÀÎ murine
leukemia virus¿¡ ÀÇÇÑ À¯ÀüÀÚ Àü´Þ È¿À²(transduction efficiency)Àº mouse ¼¼Æ÷¿¡ ºñÇØ ÀÎ
ü ¼¼Æ÷¿¡¼­´Â ÀϹÝÀûÀ¸·Î ¸Å¿ì ³·±â ¶§¹®¿¡ ½ÇÁ¦ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ Àλó À¯ÀüÀÚ ¿ä¹ý¿¡
¼­ ¸Å¿ì Å« Àå¾Ö°¡ µÇ°í ÀÖ´Ù. ±×·¯¹Ç·Î ÀÎü ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ °¨¿°È¿À²ÀÇ
Á¶»ç´Â ¾ÏÄ¡·á¸¦ À§ÇÑ À¯ÀüÀÚ¿ä¹ý¿¡ ÇʼöÀûÀÌ´Ù. ÀÎü À§¾Ï°ú °£¾Ï ¼¼Æ÷ÁÖ¸¦ ÀçÁ¶ÇÕ
retrovirus LN ¥âZ·Î transduction ½ÃŲ ÈÄ, lacZ À¯ÀüÀÚ ¹ßÇöÁ¶»ç¿¡ ÀÇÇÑ À¯ÀüÀÚ Àü´Þ°ú ¹ß
Çö È¿À² Á¶»ç¸¦ À§ÇÏ¿© 105°³ÀÇ ¾Ï¼¼Æ÷µéÀ» 6-well plate¿¡ Á¢Á¾ ÈÄ 1 mlÀÇ retroviral stock
À» °¡Áö°í ¼¼Æ÷ °¨¿°À» ½Ç½ÃÇÏ°í 48½Ã°£ ÈÄ¿¡ X-gal¿°»öÀ» ½ÃÇàÇÏ¿© ¾ó¸¶³ª ¸¹Àº ¼¼Æ÷°¡
°¨¿°µÇ¾î lacZ À¯ÀüÀÚ¸¦ ¹ßÇöÇϴ°¡¸¦ Á¶»çÇÏ¿´´Ù. ±× °á°ú ÀÎü ¾Ï ¼¼Æ÷ÁÖµéÀº mouse NIH
3T3 ¼¼Æ÷º¸´Ù 5¡­60¹èÁ¤µµ ·¹Æ®·Î¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °¨¿°È¿À²ÀÌ ³·´Ù´Â °ÍÀÌ °üÂûµÇ¾ú´Ù.
#ÃÊ·Ï#
Purpose : There are several reasons why retroviruses are useful as vectors for gene
therapy. However, retroviral vectors also have some limitations. Research in
retroviral-mediated gene transfer has struggled with low titer and transduction efficiency
on certain human target cells even with the addition of polycations to enhance
transduction. Efficient in vivo gene transfer with retroviral vectors will require the
availability of large amounts of vector at titers higher than generally possible by most
current methods. Therefore, transduction efficiency of various human cell types with
retroviral vector system is very important in human gene therapy. In an effort to test
the transduction efficiency of a retroviral vector in the human cancer cell lines, a
retroviral vector was infected into various human cancer cell lines.
Materials and Methods : We generated retrovirus producing cell lines through
trans(traction or infection of amphotropic packaging cell line PA317 with ecotropic
retroviruses encoding bacterial lacZ gene. The amphotropic retrovirus vector was used to
transduce various human cancer cell lines.
Results : Of eight randomly chosen G418-resistant clones generated by transfection,
only two clone produced the vector at up to > 106 cfu/ml, while one of
five clones generated by infection yielded higher-titer virus in the absence of helper
virus, up to 1¡¿107cfu/ml, than the transfected clones. Transduction with
supernatant derived from a PA317 producer cell line has resulted in transduction levels
from 1% to 15%, 5- to 60-fold lower than those analyzed in NIH3T3 cells.
Conclusion : These findings suggest that new improved gene transfer method into
human cancer cells using retroviruses is required for efficient in vivo cancer gene
therapy.

Å°¿öµå

Cancer gene therapy; Retroviral vector; Transduction;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS